Linde Healthcare has developed a complete solution, INOmax® Therapy, for the delivery of inhaled nitric oxide. Our solution integrates a dedicated system for administration, gas calibration, treatment recording, customer training and service support to ensure the most effective results with maximum patient safety.
In conjunction with ventilatory support and other appropriate agents, INOmax is indicated for the treatment of newborns ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
